Lasers in Medical Science

, Volume 1, Issue 4, pp 257–261 | Cite as

Practical clinical use of laser photodynamic therapy in the treatment of bladder carcinoma in situ

  • B. P. Shumaker
  • M. D. Lutz
  • G. P. Haas
  • F. Hetzel
Article

Abstract

Studies have shown that haematoporphyrin derivative (HPD) concentrates preferentially in dysplastic and neoplastic tissue, and that illumination of HPD-sensitized carcinoma with 632-nm wavelength light causes tumour destruction. We have treated 14 patients with bladder carcinoma in this way, who fit a rigid protocol, with follow-up ranging from 3–26 months. Eleven have shown no recurrence and two were considered partial responders who each showed recurrence at one year and were re-treated successfully. One patient had multiple tumours initially and responded to the point where he could be managed conventionally. One patient was lost to follow-up. Rigid patient selection and limited bladder distension reduce morbidity to transient irritative symptoms and to photosensitivity. Early clinical results have shown photodynamic therapy to be a safe and promising technique for the management of non-invasive bladder cancer in patients who are refractory to standard surgical and chemotherapeutic regimens.

Key words

Bladder carcinoma Dihaematoporphyrin ether Endocystoscopy Bladder biopsy Urine cytology 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Lipson RL, Baldes EJ, Olsen AM. The use of a derivative of hematoporphyrin in tumor detection.J Natl Cancer Inst 1961,26:1–11PubMedGoogle Scholar
  2. 2.
    Figge FHJ, Weiland GS, Mangiello LOJ. Cancer detection and therapy. Affinity of neoplastic, embryonic, and traumatized tissues for porphyrins and metalloporphyrins.Proc Soc Exp Biol Med 1948,68:640–1Google Scholar
  3. 3.
    Granelli SG, Diamond I, McDonagh AF. Wilson CB. Nielsen SL. Photochemotherapy of glioma cells by visible light and hematoporphyrin.Cancer Res 1975,35:2567–70PubMedGoogle Scholar
  4. 4.
    Hisazumi H, Miyoshi N, Naito K, Misaki T. Whole bladder wall photoradiation therapy for carcinoma in situ of the bladder: A preliminary report.J Urol 1983,131:884Google Scholar
  5. 5.
    Benson RC Jr, Farrow GM, Kinsey JH et al. Detection and localization of in situ carcinoma of the bladder with hematoporphyrin derivative.Mayo Clin Proc 1982,57:548PubMedGoogle Scholar
  6. 6.
    Benson RC Jr. Treatment of diffuse transitional cell carcinoma in situ by whole bladder hematoporphyrin derivative photodynamic therapy.J Urol 1985.134:675–8PubMedGoogle Scholar
  7. 7.
    Hisazumi H, Misaki T, Misyoshi N. Photoradiation therapy of bladder tumors.J Urol 1983,130:685PubMedGoogle Scholar
  8. 8.
    Kelly JF, Snell ME, Berenbaum MC. Photodynamic destruction of human bladder carcinoma.Br J Cancer 1975,31:237–44Google Scholar
  9. 9.
    Dougherty TJ, Lawrence G, Kaufman JH et al. Photoradiation in the treatment of recurrent breast carcinoma.J Natl Cancer Inst 1979,62:231–4PubMedGoogle Scholar
  10. 10.
    Lipson RL, Pratt AH, Baldes EJ, Dockerty MB. Hematoporphyrin derivative for detection of cervical cancer.Am J Obstet Gynecol 1964,24:178–84Google Scholar
  11. 11.
    Rasmussen-Taxdal DS, Ward GE, Figge FHJ. Fluorescence of human lymphatic cancer tissue following high doses of intravenous hematoporphyrin.Cancer 1955,8:78–81PubMedGoogle Scholar
  12. 12.
    Kinsey JH, Cortese DA, Sanderson DR. Detection of hematoporphyrin fluorescence during fiberoptic bronchoscopy to localize early bronchogenic carcinoma.Mayo Clin Proc 1978,53:594–660PubMedGoogle Scholar

Copyright information

© Bailliére Tindall 1986

Authors and Affiliations

  • B. P. Shumaker
    • 1
  • M. D. Lutz
    • 1
  • G. P. Haas
    • 1
  • F. Hetzel
    • 1
  1. 1.Department of UrologyHenry Ford HospitalDetroitUSA

Personalised recommendations